 <h1>Xadago Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>safinamide</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li>
<li>FAQ</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about safinamide. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Xadago.</p><h2>In Summary</h2><p><b>Common side effects of Xadago include:</b> dyskinesia. <b>Other side effects include:</b> hypertension and increased serum alanine aminotransferase.  See below for a comprehensive list of adverse effects.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to safinamide: oral tablet</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, safinamide (the active ingredient contained in Xadago) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking safinamide:</p><p>
<i>More common</i>
</p><ul>
<li>Blurred vision</li>
<li>dizziness</li>
<li>headache</li>
<li>nervousness</li>
<li>pounding in the ears</li>
<li>slow or fast heartbeat</li>
<li>twitching, twisting, uncontrolled repetitive movements of the tongue, lips, face, arms, or legs</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Chills</li>
<li>cold sweats</li>
<li>confusion</li>
<li>dizziness, faintness, or lightheadedness when getting up from lying or sitting position</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Agitation</li>
<li>confusion</li>
<li>diarrhea</li>
<li>feeling that others are watching you or controlling your behavior</li>
<li>feeling that others can hear your thoughts</li>
<li>feeling, seeing, or hearing things that are not there</li>
<li>fever</li>
<li>overactive reflexes</li>
<li>poor coordination</li>
<li>restlessness</li>
<li>severe mood or mental changes</li>
<li>shivering</li>
<li>sweating</li>
<li>talking or acting with excitement you cannot control</li>
<li>trembling or shaking</li>
<li>trouble breathing</li>
<li>unusual behavior</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of safinamide may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Nausea</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Acid or sour stomach</li>
<li>belching</li>
<li>cough</li>
<li>heartburn</li>
<li>indigestion</li>
<li>stomach discomfort, upset, or pain</li>
<li>trouble sleeping</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Skin rash</li>
<li>swelling of the gums and tongue</li>
</ul><p>
<!-- end oral tablet --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to safinamide: oral tablet</i></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Orthostatic hypotension, hypertension</p>
<p><b>Uncommon</b> (0.1% to 1%): Palpitations, tachycardia, sinus bradycardia, arrhythmia, hypertension, hypotension, varicose vein, QT prolongation</p>
<p><b>Rare</b> (0.01% to 0.1%): Myocardial infarction, arterial spasm, arteriosclerosis, hypertensive crisis, cardiac murmur, abnormal cardiac stress test<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Uncommon</b> (0.1% to 1%): Hyperhidrosis, pruritus, photosensitivity reaction, erythema</p>
<p><b>Rare</b> (0.01% to 0.1%): Furuncle, pyoderma, alopecia, blister, contact dermatitis, ecchymosis, lichenoid keratosis, night sweats, skin pain, pigmentation disorder, psoriasis, seborrhoic dermatitis<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Common</b> (1% to 10%): Nausea</p>
<p><b>Uncommon</b> (0.1% to 1%): Constipation, dyspepsia, vomiting, dry mouth, diarrhea, abdominal pain, gastritis, flatulence, abdominal distension, salivary hypersecretion, gastroesophageal reflux disease, aphthous stomatitis</p>
<p><b>Rare</b> (0.01% to 0.1%): Tooth infection, peptic ulcer, retching, upper gastrointestinal hemorrhage<sup>[Ref]</sup></p><h3>General</h3><p>The most commonly reported adverse events have included insomnia, dyskinesia, somnolence, nausea, orthostatic hypotension, dizziness, and headache.<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Uncommon</b> (0.1% to 1%): Urinary tract infection, nocturia, dysuria, erectile dysfunction</p>
<p><b>Rare</b> (0.01% to 0.1%): Micturition urgency, polyuria, pyuria, urinary hesitation, benign prostatic hyperplasia, breast disorder, breast pain<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Uncommon</b> (0.1% to 1%): Anemia, leukopenia, red blood cell abnormality</p>
<p><b>Rare</b> (0.01% to 0.1%): Eosinophilia, lymphopenia<sup>[Ref]</sup></p><h3>Hepatic</h3><p>Transaminase (ALT and AST) shifts from normal to above the upper limit of normal (ULN) occurred more frequently in treated patients.  During clinical trials, the percent with an ALT shift from normal to above the ULN was 5%, 7%, and 3% of patients treated with 50 mg, 100 mg, and placebo, respectively.  The percent with an AST shift from normal to above the ULN was 7%, 6%, and 3% of patients treated with 50 mg, 100 mg, and placebo, respectively.  No patients treated with this drug experienced an ALT increase that was 3 x ULN or higher.  The incidence of patients with an increase in AST to at least 3 x ULN was similar for drug treated and placebo patients.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Elevated transaminases </p>
<p><b>Uncommon</b> (0.1% to 1%): Abnormal liver function tests</p>
<p><b>Rare</b> (0.01% to 0.1%): Hyperbilirubinemia<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Uncommon</b> (0.1% to 1%): Decreased appetite, hypertriglyceridemia, increased appetite, hypercholesterolemia, hyperglycemia, weight increased, weight loss</p>
<p><b>Rare</b> (0.01% to 0.1%): Cachexia, hyperkalemia<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Uncommon</b> (0.1% to 1%): Back pain, arthralgia, muscle spasms, muscle rigidity, pain in extremity, muscular weakness, sensation of heaviness</p>
<p><b>Rare</b> (0.01% to 0.1%): Ankylosing spondylitis, flank pain, joint swelling, musculoskeletal pain, myalgia, neck pain, osteoarthritis, synovial cyst<sup>[Ref]</sup></p><h3>Nervous system</h3><p>During clinical trials, sleep attacks/sudden onset of sleep were reported in patients receiving 100 mg/day.</p>
<p></p>
<p>Dyskinesia was reported at 21%, 18%, and 9% during clinical trials of this drug at doses of 50 mg/day, 100 mg/day, or placebo.  Dyskinesia was the most frequent cause of drug discontinuation.<sup>[Ref]</sup></p><p><b>Very common</b> (greater than 10%): Dyskinesia (up to 21%) </p>
<p><b>Common</b> (1% to 10%): Somnolence, dizziness, headache, Parkinson's disease</p>
<p><b>Uncommon</b> (0.1% to 1%): Paraesthesia, balance disorder, hypoesthesia, dystonia, head discomfort, dysarthria, syncope, cognitive disorder</p>
<p><b>Rare</b> (0.01% to 0.1%): Abnormal coordination, disturbance in attention, dysgeusia, hyporeflexia, radicular pain, Restless Legs Syndrome, sedation, gait disturbance</p>
<p><b>Frequency not reported</b>: Neuroleptic malignant syndrome, serotonin syndrome, sleep attack/sudden onset of sleep<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Common</b> (1% to 10%): Cataract</p>
<p><b>Uncommon</b> (0.1% to 1%): Vision blurred, scotoma, diplopia, photophobia, retinal disorder, conjunctivitis, glaucoma</p>
<p><b>Rare</b> (0.01% to 0.1%): Amblyopia, chromatopsia, diabetic retinopathy, erythropsias, eye hemorrhage, eye pain, eyelid edema, hypermetropia, keratitis, increased lacrimation, night blindness, papilledema, presbyopia, strabismus<sup>[Ref]</sup></p><h3>Oncologic</h3><p><b>Uncommon</b> (0.1% to 1%): Basal cell carcinoma</p>
<p><b>Rare</b> (0.01% to 0.1%): Acrochordon, melanocytic nevus, seborrhoic keratosis, skin papilloma<sup>[Ref]</sup></p><h3>Other</h3><p><b>Common</b> (1% to 10%): Fall</p>
<p><b>Uncommon</b> (0.1% to 1%): Vertigo, fatigue, asthenia, pain, feeling hot</p>
<p><b>Rare</b> (0.01% to 0.1%): Feeling cold, decreased drug effect, drug intolerance, malaise, pyrexia, xerosis<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Insomnia, anxiety</p>
<p><b>Uncommon</b> (0.1% to 1%): Hallucination, depression, abnormal dreams, anxiety, confusional state, affect lability, libido increased, psychotic disorder, restlessness, sleep disorder</p>
<p><b>Rare</b> (0.01% to 0.1%): Compulsions, delirium, disorientation, illusion, impulsive behavior, loss of libido, obsessive thoughts, paranoia, premature ejaculation, sleep attacks, social phobia, suicidal ideation, gambling<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Cough, dyspnea</p>
<p><b>Uncommon</b> (0.1% to 1%): Rhinorrhea</p>
<p><b>Rare</b> (0.01% to 0.1%): Bronchopneumonia, nasopharyngitis, rhinitis, bronchospasm, dysphonia, oropharyngeal pain, oropharyngeal spasm<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p>A patient developed a hypersensitivity reaction consisting of swelling of tongue and gingiva, dyspnea, and skin rash.  With discontinuation, the symptoms resolved but reappeared with a rechallenge a month later.<sup>[Ref]</sup></p><p>Postmarketing report: Hypersensitivity reaction<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Xadago (safinamide)." US WorldMeds LLC, Louisville , KY. </p><p id="ref_2">2. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_3">3. Cerner Multum,  Inc. "Australian Product Information." O 0</p></div>
<h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2>
<ul>
<li>What foods and drugs can't I take with Xadago?</li>
</ul>
<div class="more-resources" id="moreResources">
<h2>More about Xadago (safinamide)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>2 Reviews</li>
<li>Drug class: dopaminergic antiparkinsonism agents</li>
<li>FDA Approval History</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Xadago &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Parkinson's Disease</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to safinamide: oral tablet</i></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Orthostatic hypotension, hypertension</p><p><b>Uncommon</b> (0.1% to 1%): Palpitations, tachycardia, sinus bradycardia, arrhythmia, hypertension, hypotension, varicose vein, QT prolongation</p><p><b>Rare</b> (0.01% to 0.1%): Myocardial infarction, arterial spasm, arteriosclerosis, hypertensive crisis, cardiac murmur, abnormal cardiac stress test<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Uncommon</b> (0.1% to 1%): Hyperhidrosis, pruritus, photosensitivity reaction, erythema</p><p><b>Rare</b> (0.01% to 0.1%): Furuncle, pyoderma, alopecia, blister, contact dermatitis, ecchymosis, lichenoid keratosis, night sweats, skin pain, pigmentation disorder, psoriasis, seborrhoic dermatitis<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Common</b> (1% to 10%): Nausea</p><p><b>Uncommon</b> (0.1% to 1%): Constipation, dyspepsia, vomiting, dry mouth, diarrhea, abdominal pain, gastritis, flatulence, abdominal distension, salivary hypersecretion, gastroesophageal reflux disease, aphthous stomatitis</p><p><b>Rare</b> (0.01% to 0.1%): Tooth infection, peptic ulcer, retching, upper gastrointestinal hemorrhage<sup>[Ref]</sup></p><h3>General</h3><p>The most commonly reported adverse events have included insomnia, dyskinesia, somnolence, nausea, orthostatic hypotension, dizziness, and headache.<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Uncommon</b> (0.1% to 1%): Urinary tract infection, nocturia, dysuria, erectile dysfunction</p><p><b>Rare</b> (0.01% to 0.1%): Micturition urgency, polyuria, pyuria, urinary hesitation, benign prostatic hyperplasia, breast disorder, breast pain<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Uncommon</b> (0.1% to 1%): Anemia, leukopenia, red blood cell abnormality</p><p><b>Rare</b> (0.01% to 0.1%): Eosinophilia, lymphopenia<sup>[Ref]</sup></p><h3>Hepatic</h3><p>Transaminase (ALT and AST) shifts from normal to above the upper limit of normal (ULN) occurred more frequently in treated patients.  During clinical trials, the percent with an ALT shift from normal to above the ULN was 5%, 7%, and 3% of patients treated with 50 mg, 100 mg, and placebo, respectively.  The percent with an AST shift from normal to above the ULN was 7%, 6%, and 3% of patients treated with 50 mg, 100 mg, and placebo, respectively.  No patients treated with this drug experienced an ALT increase that was 3 x ULN or higher.  The incidence of patients with an increase in AST to at least 3 x ULN was similar for drug treated and placebo patients.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Elevated transaminases </p><p><b>Uncommon</b> (0.1% to 1%): Abnormal liver function tests</p><p><b>Rare</b> (0.01% to 0.1%): Hyperbilirubinemia<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Uncommon</b> (0.1% to 1%): Decreased appetite, hypertriglyceridemia, increased appetite, hypercholesterolemia, hyperglycemia, weight increased, weight loss</p><p><b>Rare</b> (0.01% to 0.1%): Cachexia, hyperkalemia<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Uncommon</b> (0.1% to 1%): Back pain, arthralgia, muscle spasms, muscle rigidity, pain in extremity, muscular weakness, sensation of heaviness</p><p><b>Rare</b> (0.01% to 0.1%): Ankylosing spondylitis, flank pain, joint swelling, musculoskeletal pain, myalgia, neck pain, osteoarthritis, synovial cyst<sup>[Ref]</sup></p><h3>Nervous system</h3><p>During clinical trials, sleep attacks/sudden onset of sleep were reported in patients receiving 100 mg/day.</p><p></p><p>Dyskinesia was reported at 21%, 18%, and 9% during clinical trials of this drug at doses of 50 mg/day, 100 mg/day, or placebo.  Dyskinesia was the most frequent cause of drug discontinuation.<sup>[Ref]</sup></p><p><b>Very common</b> (greater than 10%): Dyskinesia (up to 21%) </p><p><b>Common</b> (1% to 10%): Somnolence, dizziness, headache, Parkinson's disease</p><p><b>Uncommon</b> (0.1% to 1%): Paraesthesia, balance disorder, hypoesthesia, dystonia, head discomfort, dysarthria, syncope, cognitive disorder</p><p><b>Rare</b> (0.01% to 0.1%): Abnormal coordination, disturbance in attention, dysgeusia, hyporeflexia, radicular pain, Restless Legs Syndrome, sedation, gait disturbance</p><p><b>Frequency not reported</b>: Neuroleptic malignant syndrome, serotonin syndrome, sleep attack/sudden onset of sleep<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Common</b> (1% to 10%): Cataract</p><p><b>Uncommon</b> (0.1% to 1%): Vision blurred, scotoma, diplopia, photophobia, retinal disorder, conjunctivitis, glaucoma</p><p><b>Rare</b> (0.01% to 0.1%): Amblyopia, chromatopsia, diabetic retinopathy, erythropsias, eye hemorrhage, eye pain, eyelid edema, hypermetropia, keratitis, increased lacrimation, night blindness, papilledema, presbyopia, strabismus<sup>[Ref]</sup></p><h3>Oncologic</h3><p><b>Uncommon</b> (0.1% to 1%): Basal cell carcinoma</p><p><b>Rare</b> (0.01% to 0.1%): Acrochordon, melanocytic nevus, seborrhoic keratosis, skin papilloma<sup>[Ref]</sup></p><h3>Other</h3><p><b>Common</b> (1% to 10%): Fall</p><p><b>Uncommon</b> (0.1% to 1%): Vertigo, fatigue, asthenia, pain, feeling hot</p><p><b>Rare</b> (0.01% to 0.1%): Feeling cold, decreased drug effect, drug intolerance, malaise, pyrexia, xerosis<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Insomnia, anxiety</p><p><b>Uncommon</b> (0.1% to 1%): Hallucination, depression, abnormal dreams, anxiety, confusional state, affect lability, libido increased, psychotic disorder, restlessness, sleep disorder</p><p><b>Rare</b> (0.01% to 0.1%): Compulsions, delirium, disorientation, illusion, impulsive behavior, loss of libido, obsessive thoughts, paranoia, premature ejaculation, sleep attacks, social phobia, suicidal ideation, gambling<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Cough, dyspnea</p><p><b>Uncommon</b> (0.1% to 1%): Rhinorrhea</p><p><b>Rare</b> (0.01% to 0.1%): Bronchopneumonia, nasopharyngitis, rhinitis, bronchospasm, dysphonia, oropharyngeal pain, oropharyngeal spasm<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p>A patient developed a hypersensitivity reaction consisting of swelling of tongue and gingiva, dyspnea, and skin rash.  With discontinuation, the symptoms resolved but reappeared with a rechallenge a month later.<sup>[Ref]</sup></p><p>Postmarketing report: Hypersensitivity reaction<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Xadago (safinamide)." US WorldMeds LLC, Louisville , KY. </p><p id="ref_2">2. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_3">3. Cerner Multum,  Inc. "Australian Product Information." O 0</p><h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2><ul>
<li>What foods and drugs can't I take with Xadago?</li>
</ul><h2>More about Xadago (safinamide)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>2 Reviews</li>
<li>Drug class: dopaminergic antiparkinsonism agents</li>
<li>FDA Approval History</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Xadago &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Parkinson's Disease</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>